Pancreatic ductal adenocarcinoma (PDAC) is an aggressive neoplastic disease. Gemcitabine, the currently used chemotherapeutic drug for PDAC, elicits only minor benefits, because of the development of escape pathways leading to chemoresistance. Herein, we aimed at investigating the involvement of the mitogen activating protein kinase interacting kinase (MNK)/eIF4E pathway in the acquired drug resistance of PDAC cells. Screening of a cohort of PDAC patients by immunohistochemistry showed that eIF4E phosphorylation correlated with disease grade, early onset of disease and worse prognosis. In PDAC cell lines, chemotherapeutic drugs induced MNK-dependent phosphorylation of eIF4E. Importantly, pharmacological inhibition of MNK activity synergistically enhanced the cytostatic effect of gemcitabine, by promoting apoptosis. RNA interference (RNAi) experiments indicated that MNK2 is mainly responsible for eIF4E phosphorylation and gemcitabine resistance in PDAC cells. Furthermore, we found that gemcitabine induced the expression of the oncogenic splicing factor SRSF1 and splicing of MNK2b, a splice variant that overrides upstream regulatory pathways and confers increased resistance to the drug. Silencing of SRSF1 by RNAi abolished this splicing event and recapitulated the effects of MNK pharmacological or genetic inhibition on eIF4E phosphorylation and apoptosis in gemcitabinetreated cells. Our results highlight a novel pro-survival pathway triggered by gemcitabine in PDAC cells, which leads to MNK2-dependent phosphorylation of eIF4E, suggesting that the MNK/eIF4E pathway represents an escape route utilized by PDAC cells to withstand chemotherapeutic treatments.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant neoplastic disease. 1 Gemcitabine, the elective agent used in PDAC chemotherapy, exerts only marginal survival benefits, 1 urging for the identification of new agents and/or therapeutic targets. In this regard, as the PI3K/AKT/mTOR (mammalian target of rapamycin) pathway is activated in approximately half of PDACs, correlating with poor prognosis, 2 mTOR inhibitors are being considered as possible therapeutic agents in combination with chemotherapy. Nevertheless, their efficacy is often limited by activation of escape pathways leading to phosphorylation of AKT and eIF4E in response to mTOR inhibition. 3, 4 For these reasons, characterization of the molecular mechanisms involved in the acquisition of drug resistance represents a clinical priority.
The mTOR serine/threonine kinase is a central regulator of protein synthesis and cell growth. 5 mTOR modulates the activity of eIF4E, the core component of the translation initiation complex eIF4F that assembles at the 5 0 cap of eukaryotic mRNAs. 5 In quiescent cells, eIF4E activity is restricted by the 4EBPs (eIF4E-binding proteins). [5] [6] [7] Nutrients induce phosphorylation of 4EBPs by mTOR, thereby causing their release from eIF4E and assembly of eIF4F. 5 Furthermore, eIF4E indirectly stimulates translation by favoring nuclear export of selected mRNAs. 6 In line with its central role in cell growth, increased eIF4E levels can promote neoplastic transformation. 7 An additional layer of regulation of eIF4E is provided by its phosphorylation in serine 209 by the mitogen activated protein kinase (MAPK) interacting kinases (MNK) MNK1 and MNK2, 8, 9 which are activated by ERK1/2 and p38. 9 Phosphorylation of eIF4E occurs in cells exposed to growth factors and chemotherapeutic agents, 9, 10 and its pharmacological inhibition was shown to reduce proliferation in cancer cells. [11] [12] [13] Importantly, although phosphorylation of eIF4E by MNKs is dispensable for basal protein synthesis and cell viability, 8 it is essential for the transforming activity of eIF4E in mouse models of cancer, [14] [15] [16] and it positively correlates with poor prognosis and disease grade in human prostate and lung cancers. 17, 18 These observations point to eIF4E phosphorylation as a key step in oncogenic transformation. Noteworthy, as suppression of eIF4E phosphorylation sensitizes cancer cells to growth arrest 11 and stress-induced death 19 without affecting normal development or lifespan in animal models, 8 the MNK/eIF4E pathway appears as a promising pharmacological target for cancer treatment.
Herein, we have investigated the regulation and function of the MNK/eIF4E pathway in PDAC. Phosphorylation of eIF4E positively correlated with grade, and was associated with worse prognosis and earlier disease onset in PDAC patients. MNK2-dependent phosphorylation of eIF4E was induced by gemcitabine in PDAC cells. The drug also promoted upregulation of the splicing factor SRSF1 and splicing of MNK2b, a splice variant that overrides upstream regulatory pathways 9, 20 and confers increased resistance to gemcitabine. Suppression of this pathway by pharmacological or genetic inhibition of either MNKs or SRSF1 1 synergistically enhanced the cytotoxic effects of gemcitabine. Our results highlight a novel pro-survival pathway triggered by gemcitabine in PDAC cells, which leads to MNK2-dependent phosphorylation of eIF4E, suggesting that the MNK/eIF4E pathway might represent a promising therapeutic target for PDAC.
RESULTS
Increased phosphorylation of eIF4E in PDAC correlates with worse prognosis A cohort of 32 patients diagnosed with primary PDAC in the absence of metastases, who received surgery with radical intent (see Supplementary Table 1) , was analyzed for the levels of the phosphorylated form of eIF4E (p-eIF4E) by immunohistochemistry. We found that 27 samples (84.3%) stained positive for p-eIF4E ( Figure 1a, Supplementary Table 1) . A linear score of staining (range 0-5) was assigned to the samples (Figure 1a ; see Materials and methods), and patients were subdivided in two groups: group 0 comprised eight samples displaying no staining (score 0) or low p-eIF4E staining (that is, p2), whereas group 1 comprised 24 samples displaying strong p-eIF4E staining (that is, X3) ( Figure 1b ). The two groups displayed statistically significant differences only for age at diagnosis, grading, progression-free survival and overall survival (Figure 1b ). Group 1 patients had a mean age at diagnosis of 64.5, with 95% confidence interval (CI) 59.8-69.2, whereas patients with a low p-eIF4E score (group 0) had a significantly higher mean age at diagnosis of 74.2 (95% CI: 71.9-76.5; P ¼ 0.02) (Figure 1b) . Notably, of the eight patients diagnosed at age p60, four had a p-eIF4E score of 5, three had a score of 4 and one a score of 3 (Supplementary Table 1) . Furthermore, the p-eIF4E score was positively correlated with tumor grade (G grade, range 1-3; Spearman's coefficient of rank correlation (r) ¼ 0.6, P ¼ 0.0008).
The high p-eIF4E score was also associated with worse survival probability (log-rank test P ¼ 0.02, Figure 1c) . Similarly, in a Coxproportional hazards regression model, high p-eIF4E score was associated with worse survival (hazard ratio 4.6; 95% CI: 1-20.1). Adjuvant therapy (gemcitabine) was associated with a better overall survival in the Cox-proportional hazards regression model (hazard ratio 0.3; 95% CI: 0.12-0.85), whereas neither the resection margins (R status), nor the lymph node status (N stage or lymph node ratio) were. The mean survival of group 0 patients was 25.1 months (95% CI: 11.3-38.8) as compared with 13 months (95% CI: 8.2-17.8) in group 1 patients (P ¼ 0.04) (Figure 1b) . Elevated p-eIF4E was also associated with shorter 'recurrence-free survival' (log-rank test P ¼ 0.018). Accordingly, the mean time to tumor recurrence was 20.6 months for group 0 and 9 months for group 1 (P ¼ 0.02) (Figure 1b) . Collectively, these data suggest that eIF4E phosphorylation is directly correlated with tumor grade and associated with worse survival probability.
Therapeutic drugs induce eIF4E phosphorylation in PDAC cells
The marginal survival benefits observed in patients 1 may suggest that chemotherapeutic treatments trigger the activation of prosurvival pathways in PDAC cells. The MNK/eIF4E and the AKT/ mTOR pathways are two pro-survival routes frequently activated in cancer. 3, 4 To test whether they contribute to drug resistance in PDAC cells, we analyzed activation of key proteins in these pathways. Phosphorylation of eIF4E was induced by treatment with gemcitabine in several poorly differentiated PDAC cell lines, such as MiaPaCa2 (Figure 2a Figure S1A) . Activation of the MNK/ eIF4E pathway was a specific response, as no increase in AKT phosphorylation occurred under these conditions (data not shown), whereas the decreased phosphorylation of the ribosomal protein rpS6 indicated that the mTOR pathway was inhibited by gemcitabine (Figures 2a,b) .
Next, we tested whether activation of the MNK/eIF4E pathway was triggered by other chemotherapeutic treatments. eIF4E phosphorylation was also increased in response to cisplatin in PDAC cells (Supplementary Figure S1B) , whereas neither phosphorylation of AKT (data not shown) nor activation of the mTOR pathway were observed (Supplementary Figure S1B) . PDAC cells were also treated with the mTOR inhibitor rapamycin (1 and 10 nM) for up to 24 h. As for other cancer cells, 3, 4 mTOR inhibition caused an increase in phosphorylation of both AKT and eIF4E in PDAC cells (Supplementary Figures S1C, D) . However, AKT phosphorylation returned to basal levels by 4-24 h of treatment with the higher dose of rapamycin, whereas eIF4E phosphorylation persisted for the whole duration of the experiment, regardless of the dose used (Supplementary Figures S1C, D) . These results suggest that eIF4E phosphorylation is a general, long-lasting feedback response of PDAC cells to therapeutic treatments.
Inhibition of eIF4E phosphorylation enhances the cytostatic effect of therapeutic drugs To test the most effective tool to interfere with eIF4E phosphorylation in PDAC cells, we treated them with inhibitors of kinases acting upstream of the MAPK/MNK pathway. 9 The PI3K inhibitor (LY294002), MEK1/2 inhibitor (U0126) and p38 inhibitor (SB202190), alone or in combination, only partially reverted the increased phosphorylation of eIF4E induced by gemcitabine and rapamycin in the poorly differentiated MiaPaCa2 and PT45P1 cell lines (Supplementary Figures S2A, B) . However, direct inhibition of MNKs by their chemical inhibitor MNK-I completely abolished eIF4E phosphorylation under all treatments (Supplementary Figure S2A,B) . Moreover, MNK-I also strongly reduced gemcitabine-induced eIF4E phosphorylation in the well-differentiated HPAF2 cells (Supplementary Figure S2C) . Thus, MNK-I was selected for further studies.
Dose-response experiments showed that MiaPaCa2 cells were highly resistant to gemcitabine, with less than 50% growth inhibition at 100 nM (Supplementary Figure S3A) , whereas an almost complete suppression of PT45P1 cell growth was achieved at 30 nM (Supplementary Figure S3B) . Thus, to test the effect of MNK-I on PDAC cell growth, we used sub-optimal doses of gemcitabine (30 nM for MiaPaCa2 and 0.1 nM for PT45P1). MNK-I alone slightly reduced growth of both cell lines (Figures 2c, d) , to an extent similar to the sub-optimal doses of gemcitabine. However, the combined treatment with the two drugs synergistically inhibited PDAC cell growth, with an almost complete block achieved in PT45P1. A similar synergic effect was also observed in the well-differentiated HPAF2 cells (Supplementary Figure S3C) . Furthermore, inhibition of eIF4E phoshorylation by MNK-I significantly augmented the cytostatic effects of cisplatin and rapamycin (Supplementary Figures S3D, E) , indicating that activation of this pathway exerts a general positive effect in the stress response of PDAC cells.
Inhibition of MNK activity enhances gemcitabine-induced apoptosis in MiaPaCa2 cells
Clonogenic assays were performed to directly test whether MNK-I enhanced the cytotoxic activity of gemcitabine. MiaPaCa2 cells, which were chosen for their higher resistance to the drug, were cultured for 24 h with sub-optimal doses of gemcitabine (0.1-0.3 nM) with or without MNK-I (10 mM) and then grown for 10 days in complete medium (±5 mM MNK-I). Under these conditions, MNK-I suppressed eIF4E phosphorylation in the large majority of the cells (Supplementary Figure S4A) . Gemcitabine reduced the number of colonies in a dose-dependent manner, whereas MNK-I did not significantly affect their number (Figure 3b ), even though it reduced the size of colonies eIF4E phosphorylation and drug resistance in PDAC L Adesso et al Figure S4C ) documented that MNK-I significantly increased cell death in cells exposed to gemcitabine, even though it did not trigger apoptosis when it was administered alone (Figures 3c, d) . Notably, MNK-I also enhanced the cytotoxic effects of cisplatin in MiaPaCa2 cells (Supplementary Figure S4D) . These results suggest that the synergic inhibitory effect on cell growth and colony formation exerted by MNK-I is mainly because of enhanced apoptosis in gemcitabine-treated cells.
MNK2 is required for resistance of MiaPaCa2 cells to gemcitabine To overcome possible off-target effects of MNK-I, we set out to interfere with MNK1/2 function by other means. MiaPaCa2 cells were transfected with MNK1 and MNK2 siRNAs (small interference RNAs) and depletion of the mRNAs corresponding to both splice variants was determined by RT-PCR (Figure 4a ). Decreased expression of either MNK1 or MNK2 protein (Figure 4b ) reduced eIF4E phosphorylation under basal conditions, with MNK2 exerting a stronger effect (Figure 4c) . Furthermore, the increased phosphorylation of eIF4E triggered by gemcitabine was completely suppressed after silencing of MNK2, whereas MNK1 depletion only slightly reduced it (Figure 4c ). Silencing of MNK2 suppressed gemcitabine-induced eIF4E phosphorylation also in PT45P1 and HPAF2 cells (Supplementary Figure S5A) . These results suggest that MNK2 is predominantly responsible for eIF4E phosphorylation in PDAC cells treated with gemcitabine.
Next, MiaPaCa2 cells transfected with si-MNK1 and si-MNK2 were cultured with or without gemcitabine for 48 h. In the absence of the drug, silencing of either MNK1 or MNK2 caused a small reduction of cell growth (15-20%) compared with cells transfected with a control siRNA, whereas concomitant silencing of both MNKs elicited an additive effect (40% inhibition) (Figure 4d ). However, in the presence of gemcitabine, which caused a 40% reduction in cell growth per se (Figure 4d ), the effect of MNK2 depletion was significantly stronger than MNK1 depletion (75% inhibition vs 60% inhibition). Moreover, depletion of both kinases did not significantly increase the effect of MNK2 depletion alone in cells treated with gemcitabine (Figure 4d ).
To investigate whether reduced growth was ascribable to increased cell death, as in the case of the MNK-I, we analyzed Figures S5B, C) . These results strongly suggest that MNK2-dependent phosphorylation of eIF4E contributes to the protective response of PDAC cells to gemcitabine.
SRSF1 promotes splicing of the MNK2b variant in gemcitabinetreated MiaPaCa2 cells On the basis of its prominent role in the response of PDAC cells to gemcitabine, we focused on MNK2. The MKNK2 gene encodes two splice variants, named MNK2a and MNK2b. 9 Notably, the b variant lacks the MAPK-interacting domain, 20 which uncouples its activation from this upstream pathway (Figure 5a) . 9, 20, 21 Treatment with gemcitabine for 48 and 72 h modulated the expression of MKNK2 in PDAC cells, by causing a reduction in expression of MNK2 (Figure 5b ; Supplementary Figure S6A) . Concomitantly with the reduction, gemcitabine also altered the ratio between the MNK2 splice variants in favor of MNK2b (Figure 5b; Supplementary Figure S6A) . Importantly, we found that expression of recombinant GFP-MNK2b attenuated gemcitabine-dependent cell death in transfected MiaPaCa2 cells, whereas transfection of GFP-MNK2a did not exert any effect (Figure 5c; Supplementary Figure S6B ). This result suggests that the shift toward the MNK2b variant in response to the treatment of MiaPaCa2 cells with gemcitabine contributes to reduce their sensitivity to the drug. In other cell types splicing of MNK2b is promoted by SRSF1, a splicing factor of the SR protein family that functions as a protooncogene in vitro and in vivo. 21 Remarkably, gemcitabine induced expression of SRSF1 in MiaPaCa2 and PT45P1 cells (Figure 5d ). SRSF1 upregulation was specific because other oncogenic splicing factors, such as hnRNPA1 22 and Sam68, 23 were not affected (Figure 5d ). To investigate the role of SRSF1 in the alternative splicing of MNK2, we silenced it by RNAi. SRSF1 mRNA was decreased already at 24 h from transfection (Supplementary Figure S7) , but SRSF1 protein depletion was only observed after 48 h and correlated with increased splicing of the MNK2a variant (Figure 6a ). At this time-point, MiaPaCa2 cells were treated with gemcitabine for 48 h and analyzed for MNK2b expression and eIF4E phosphorylation levels. Although SRSF1 silencing did not affect eIF4E phosphorylation in cells growing in control medium (Figures 6a, b) , it dramatically reduced it in gemcitabine-treated cells (Figure 6b) . Moreover, SRSF1 depletion prevented the gemcitabine-induced shift of variants ratio toward MNK2b (Figure 6b) , without affecting the reduction in the total levels of MNK2. These changes in MNK2 splicing and eIF4E phosphorylation were paralleled by reduced proliferation (Figure 6c ) and increased death (Figure 6d ) in SRSF1-depleted cells exposed to gemcitabine, similarly to what observed by MNK2 silencing and pharmacological inhibition of MNK activity.
Collectively, these observations strongly suggest that upon exposure to gemcitabine, PDAC cells activate a pro-survival pathway that involves upregulation of SRSF1, splicing of the MNK2b variant and increased phosphorylation of eIF4E. DISCUSSION PDAC is a non curable disease, mainly owing to late diagnosis and resistance to therapies, which results in rapid progression and metastatic spreading. 1 In this work, we found that various therapeutic treatments trigger MNK-dependent phosphorylation of eIF4E in PDAC cell models. The biological relevance of this phenomenon is indicated by the enhanced cell death in response to gemcitabine observed in PDAC cells in which eIF4E phosphorylation is prevented by pharmacological or genetic approaches. Furthermore, increased phosphorylation of eIF4E correlates with worse prognosis and disease grade in patients. Thus, these results suggest that the MNK/eIF4E pathway might represent a novel potential therapeutic target for PDAC.
Phosphorylation of eIF4E is associated with worse prognosis in lung cancer, 18 and it is required for the oncogenic properties of eIF4E in animal models. [14] [15] [16] To investigate whether phosphorylation of eIF4E displays clinical relevance in PDAC, we analyzed a cohort of 32 patients selected for the availability of detailed clinical and histopathological data and for the absence of metastases at diagnosis. We found that increased phosphorylation of eIF4E positively correlated with disease grade and was significantly associated with early disease onset in PDAC patients. Furthermore, high eIF4E phosphorylation levels were also associated with worse survival and with a shorter mean time to tumor recurrence. Although the cohort examined in our study was relatively small, our results were statistically significant. However, as some of the patients were also lost to follow-up relatively early, more extensive analyses with larger patient numbers will be required to confirm that eIF4E phosphorylation may represent an important prognostic marker for PDAC. A larger cohort will also be necessary to determine whether increased eIF4E phosphorylation levels reflect an underlying biology associated with earlier onset and more aggressive disease.
Increased phosphorylation of eIF4E occurs in cancer cells of various organs after exposure to stress stimuli and chemotherapeutic treatments, [9] [10] [11] [12] [13] [14] [15] [16] thus suggesting that this pathway allows cells to survive under adaptive pressures. Our results now indicate that MNK-dependent phosphorylation of eIF4E also promotes survival of PDAC cells exposed to therapeutic drugs. Although pharmacological inhibition of MNK activity had mild effects on cell growth, it strongly enhanced the cytostatic effect exerted by genotoxic stress and mTOR inhibition. Our studies indicate that MNK-I mainly affects cell survival in response to gemcitabine. Importantly, sub-optimal doses of gemcitabine combined with MNK-I were sufficient to completely prevent colony formation. As MNK activity and eIF4E phosphorylation are dispensable for normal organism development, 8 inhibition of this pathway might be well tolerated in combination with other therapeutic treatments. In this regard, it also appears promising the recent observation that inhibition of eIF4E activity by ribavirin exhibited substantial clinical benefits in acute myeloid leukemia patients without eliciting toxic responses. 24 As chemotherapeutic regimens exert only marginal effects in PDAC patients, 1 our findings on the possible role of eIF4E phosphorylation in drug sensitivity of PDAC cells suggest that targeting eIF4E phosphorylation might represent a novel strategy to improve therapeutic efficacy. Notably, this approach might also be useful in combination with other targeted therapies currently under evaluation in PDAC. For instance, RAD001 (Everolimus), a small-molecule mTOR inhibitor derived from rapamycin, exerted positive effects in combination with gemcitabine in preclinical and clinical studies with metastatic PDAC patients. 25 However, a side effect of blocking mTOR activity is the increased MNK-dependent phosphorylation of eIF4E. 3, 4 As inhibition of MNK activity synergistically enhances the cytostatic effect of mTOR inhibitors in PDAC cells, it is possible that combined treatment with these molecules might exert beneficial effects.
Phosphorylation of eIF4E promotes tumor development in vivo. [14] [15] [16] The activation of MNKs and eIF4E phosphorylation reported in several human cancer cell lines further support the implication of this pathway in oncogenesis. [11] [12] [13] In line with this hypothesis, pharmacological inhibition of MNK activity was shown to reduce protein synthesis, 11 cancer cell proliferation [11] [12] [13] and development of tumors in vivo. 12 However, all these studies did not document a clear difference between the contribution of MNK1 and MNK2 to these processes. Our work now suggests that, although both kinases contribute to eIF4E phosphorylation and support PDAC cell proliferation under basal conditions, only MNK2 is responsible for the pro-survival effects in cells treated with gemcitabine. Thus, our results uncover a new MNK2-specific function in PDAC cells, which confers resistance to a genotoxic treatment. As MNK2 was found to be upregulated in hormoneresistant prostate cancer, 12 it will be interesting to test whether it is more generally involved in the pro-survival responses of cells that develop resistance to chemotherapeutic treatments.
The MKNK2 gene encodes two mRNA variants, through usage of alternative last exons named 13a (MNK2a) and 13b (MNK2b). 9, 20 Gemcitabine caused a reduction in MNK2 expression, mainly affecting MNK2a levels and thereby altering the splice variant ratio in favor of MNK2b. We also found that MNK2b partially protected cells from gemcitabine-induced apoptosis, whereas MNK2a did not. MNK2b lacks the MAPK-interacting region and it is thereby uncoupled from upstream MAPK pathways. 9, 20, 21 Thus, it is possible that its expression in cells treated with gemcitabine allows higher levels of eIF4E phosphorylation independently from external cues, which might lead to progressive selection of chemoresistant cells. Splicing of MNK2b was previously shown to be regulated by the splicing factor SRSF1 in other cell types. 21 We found that gemcitabine induces the expression of SRSF1 in PDAC cells, which is necessary to favor MNK2b splicing under genotoxic stress. In the absence of SRSF1, gemcitabine still caused a reduction in MNK2 levels, but it did not alter the ratio between the two splice variants, indicating that SRSF1 is required to promote MNK2b splicing in PDAC cells exposed to the drug. Moreover, SRSF1 silencing impaired eIF4E phosphorylation and reduced viability of PDAC cells exposed to gemcitabine. These observations suggest that SRSF1 upregulation is part of the pro-survival response triggered by gemcitabine. Interestingly, SRSF1 is an oncogene frequently upregulated in cancer. 21 More in general, splicing factors are emerging as novel regulators of oncogenic transformation, and increased expression of some of them was shown to correlate with malignancy and poor prognosis. 22 Furthermore, mutations that affect splicing of tumor suppressors, such as BRCA1/2 and APC, resulting in their inactivation, account for some types of inherited and sporadic susceptibility to cancer. 26, 27 Our results now suggest that increased expression of splicing factors and changes in alternative splicing of target genes can also occur in response to chemotherapeutic treatment of cancer cells. Thus, targeting the activity of splicing factors might represent a novel approach for combined treatments of specific cancers. In this regard, it is noteworthy that the SR protein kinase 1, a key regulator of SRSF1 activity, is also upregulated in PDAC 28 and was proposed as a suitable target for novel therapies. 29 In conclusion, our study identifies a novel pro-survival pathway triggered by gemcitabine in PDAC cells, which relies on MNK2-dependent phosphorylation of eIF4E, and suggests that targeting this pathway might represent a promising approach to enhance the response of PDAC cells to therapeutic agents.
MATERIALS AND METHODS

Tissue, histopathology and clinical information
Immunohistochemistry was performed with a rabbit polyclonal anti phospho-eIF4E antibody (1:200, Invitrogen, Rockville, MD, USA), as previously described, 18 on paraffin-embedded tissue samples from 32 primary non metastatic PDAC patients receiving surgery with radical intent. All but eight of these patients received gemcitabine-based adjuvant therapy after surgery. None of the patients received neoadjuvant treatment. Clinical and histopathological data for each patient were recorded (Supplementary Table 1 ). Scoring of p-eIF4E was based on distribution and intensity of staining in neoplastic cells. 18 Distribution was scored as 0 (0%), 1 (1-50%) and 2 (51-100%). Intensity was scored as 0 (no signal), 1 (mild), 2 (intermediate), 3 (strong) (Figure 1a ). Values were summed in a total score from 0 to 5. Samples were classified as 'low p-eIF4E' expression when score was p2 (group 0), and as 'high p-eIF4E' expression when score was X3 (group 1). Statistical analysis was performed by MedCalc 9.6 (www.medcalc.be). Differences for continuous variables were evaluated by t-test and for categorical variables by Fisher's test. Correlation between the expression scores and pathological data was tested by Spearman's rank order correlation. Analysis of overall survival was performed by Kaplan-Meier method and analyzed by log-rank test. Patients lost at follow-up or whose follow-up ended before the outcome (death) was reached, are 'censored' and marked as small vertical lines in the survival curves. Univariate and multivariate analyses for risk factors affecting survival were performed by Cox-proportional hazards regression model test; a P-value o0.05 was considered as statistically significant.
Cell cultures, treatments and extract preparation After incubation, cells were washed with ice-cold phosphate buffered saline (PBS), resuspended in lysis buffer (100 mM NaCl, 15 mM MgCl 2 , 30 mM Tris-HCl pH 7.5, 1 mM dithiothreitol, 2 mM Na-ortovanadate, 1% Triton X-100 and Protease-Inhibitor Cocktail (Sigma-Aldrich)) and kept on ice for 10 min. Cell extracts were separated by centrifugation at 12 000 r.p.m. for 10 min and diluted in SDS-PAGE sample buffer.
SDS-PAGE and western blot analyses
Western blot analyses of cell extracts (30 mg) were performed as previously described 11, 30 using the following primary antibody: mouse anti beta tubulin (1:1000, Sigma-Aldrich); rabbit anti-4EBP1, anti-rpS6 and anti-eIF4E (1:1000, Cell Signaling Technology, Danvers, MA, USA); rabbit anti-p-rpS6 and anti p-eIF4E (1:1000, Biosource, Carlsbad, CA, USA); mouse anti-SRSF1 and anti-hnRNPA1, rabbit anti-Sam68 and anti-ERK2 (1:1000, SantaCruz Biotechnology, Santa Cruz, CA, USA). Secondary IgGs conjugated with horseradish peroxidase (1:10 000; Amersham Bioscience, Piscataway, NJ, USA) were incubated for 1 h at room temperature and signals were detected by enhanced chemiluminescence (SantaCruz Biotechnology).
Cell count and viability assays
MiaPaCa2 were seeded at 50 000 cells/plate in 24-well plate and treated as described in the text for 72 h, washed in PBS, trypsinized and counted using the Thoma's chamber. 
Colony formation assay
Single-cell suspensions were plated in 100 mm plates (3500 cells/plate). After 1 day, cells were treated for 24 h with gemcitabine (0.1 and 0.3 nM) and MNK-I (10 mM) alone or in combination. At the end of the incubation, the medium was replaced every 24 h with or without addition of 5 mM MNK-I. After 10 days, cells were fixed in methanol for 10 min, stained overnight with 10% Giemsa, washed twice in PBS and dried. Pictures were taken using a digital camera to count the colonies. Results represent the mean±s.d. of three experiments.
Immunofluorescence analysis
For eIF4E phosphorylation, MiaPaCa2 were seeded at 350 000 cells/plate in 35 mm dishes and treated with 30 nM gemcitabine with or without 10 mM MNK-I for 24 h. Cell lines were then fixed for 10 min in 4% paraformaldehyde (PFA), permeabilized with 0.1% Triton X-100, processed for immunofluorescence analysis using the anti p-eIF4E (1:200). For apoptotic markers, cells were seeded at 250 000 (MiaPaCa2, HPAF2) or 200 000 (PT45P1) cells/plate in 35 mm plates and treated with gemcitabine for 72 or 48 h. Immunofluorescence was performed as described above and cell were stained with anti-cleaved caspase-3 antibody (1:500; Sigma-Aldrich). For TUNEL assays, fixed cells were permeabilized in PBS containing 0.1% sodium citrate and 0.1% Triton X-100 and incubated with TUNEL reaction mixture containing terminal deoxynucleotidyltransferase and fluoresceindUTPs at 37 1C for 60 min (In Situ Cell Death Detection Kit, Fluorescein, Roche, Penzberg, Germany). Four random fields were chosen for each treatment and at least 100 cells/field were counted. Results represent the mean ± s.d. of three experiments.
Cell transfection experiments pEGFP MNK2a and pEGFP MNK2b vectors were obtained by subcloning the EcoRI/SalI (MNK2a, 2b) fragments from pEBG (MNK2a) or pCMV5 (MNK2b) (generous gift of Dr CG Proud) in pEGFPC1 vector. MiaPaCa2 cells were transfected in 35 mM plates with 2 mg of plasmid using Lipofectamine 2000 (Invitrogen) by standard methods as described. 30, 31 MNK1 silencing was obtained using the Smart pool reagent mix from Dharmacon. MNK2 si-RNA 5 0 -GGAACGUCCUAGAGCUGAU-3 0 (common to both splice variants of the gene) and SRSF1 si-RNA 5 0 -CCAAGGACAUU GAGGACGU-3 0 were purchased from Sigma-Aldrich. Cells were transfected at 50% confluence in 35 mM plates with 30 nM of siRNAs using Lipofectamine RNAi MAX reagent (Invitrogen). 31 RT-PCR analyses RNA was extracted using the TRIzol reagent (Invitrogen) and following manufacturer's instruction. After digestion with RNase-free DNase (Roche Diagnostics GmbH), 1 mg of RNA was retro-transcribed (RT) using M-MLV reverse transcriptase (Invitrogen). PCR primers for MNK1 and MNK2 splice variants and PCR conditions were previously described. 21, 32 For MNK1 and MNK2 expression we used primers that amplify both splice variants: MNK1 forward 5 0 -GAGGTTCCATCTTAGCCCACAT-3 0 , reverse 5 0 -ACGATGAGCAAT GCCTTTGGT-3 0 ; MNK2 forward 5 0 -CGCCTTGGACTTTCTGCATAA-3 0 , reverse 5 0 -TCACAGATCTTCACGGGGGA-3 0 . For SRSF1 expression, the following primers were used: forward 5 0 -ATGTCGGGAGGTGGTGTGATTCGT-3 0 , reverse 5 0 -TTATGT ACGAGAGCGAGATCTGCT-3 0 . Ten percent of the RT reaction was used for each PCR reaction.
